Microdosing of Protein Drugs

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 2, 2016, Pages 150-152

  Rowland, M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CARBON 14; DRUG; IODINE 129; LYSINE; PROTEIN DRUG; RECOMBINANT PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ALLOMETRY; BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MICRODOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GOOD MANUFACTURING PRACTICE; HUMAN; PHARMACOKINETICS; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; VOLUME OF DISTRIBUTION; ANIMAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; MOLECULAR WEIGHT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS;

EID: 84957311181     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.275     Document Type: Review

References (10)

1. Lappin, G. & Garner, R. C. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2, 233-240 (2003).
2. Lappin, G., Noveck, R. & Burt, T. Microdosing and drug development: past, present and future. Expert Opin. Drug Metab. Toxicol. 9, 817-834 (2013).
3. Vlaming, M. L. H. et al. Microdosing of a carbon-14 labeled protein in healthy volunteers accurately predicts its pharmacokinetics at therapeutic dosages. Clin. Pharmacol. Ther. 98, 196-204 (2015).
4. Fijnvandraat, K. et al. Recombinant, B-domain deleted factor VIII (r-VIIISQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb. Haemost. 77, 298-302 (1997).
5. Verstraete, M., Bounameaux, H., de Cock, F., Van de Werf, F. & Collen, D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J. Pharmacol. Exp. Ther. 235, 506-512 (1985).
6. Jusko, W. J. & Ko, H. C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56, 406-419 (1994).
7. Wang, W. & Prueksaritanont, T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm. Drug Dispos. 31, 253-263 (2010).
8. Lamers, R. J., de Jong, A. F., Lopez-Gutierrez, J. M. & Gomez-Guzman, J. Iodine-129 microdosing for protein and peptide drug development: erythromycin as a case study. Bioanalysis. 5, 53-63 (2013).
9. Woo, S. & Jusko, W. J. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab. Dispos. 35, 1672-1678 (2007).
10. Bosgra S., Vlaming, M. L. H. & Vaes, W. H. J. To apply microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics. Clin. Pharmacokin. (2015); e-pub ahead of print (doi 10. 1007/s40262-015-0308-9).